Extracellular Vesicles as a Novel Therapeutic Option in Liver Transplantation

Kristin Carlson, John Kink, Peiman Hematti, David P. Al‐Adra – 25 August 2020 – Longterm liver graft dysfunction and immunological rejection remain common adverse events, in part due to early acute rejection episodes initiated by ischemia/reperfusion injury (IRI) immediately following transplantation. Novel treatment methods are therefore required to ameliorate liver IRI and to promote longterm allograft acceptance.

Subscribe to